The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics  Today, Company discloses first clinical data from the TCR Bispecific molecule, TCER® IMA402 targeting PRAME, in the Phase 1 dose escalation trial, demonstrating a favorable tolerability profile and signs of dose-dependent and PRAME expression-dependent clinical activity, including first objective responses in melanoma patients; early pharmacokinetics data ...

The market expects Immatics (IMTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they ...

Immatics (NASDAQ: IMTX ) is an early-stage biotech that focuses on cell-based immunotherapies, also known as Adoptive Cell Therapy (ACT), for solid cancers. I believe their stock is promising and is a buy(bullish) based on my analysis of their I graduated with an M.D from the University of Pavia, Italy. Soon after starting my clinical career I realized I was much more drawn towards statistics and analyzing clinical trials/research. Around that time I was also introduced to the world of Finance and realized ...

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cellredirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be ...

On Thursday, Immatics N.V. IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million. The company also announced updated Phase 1b data on ACTengine IMA203 TCR-T targeting PRAME in melanoma patients and provided an update on SUPRAME, the upcoming Phase 3 trial to evaluate IMA203 in metastatic melanoma patients. As of August 23, 2024, 28 heavily pretreated patients with metastatic melanoma were treated with IMA203 at the recommended Phase 2 dose (RP2D, 1 to 10 bil ...

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cellredirecting cancer immunotherapies, announced today the commencement of an underwritten public offering of its ordinary shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offe ...

Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS) Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regul ...

Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming oral and poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6 - 10, 2024. Full abstracts will be available on November 5, 2024, at 9:00 am EST in the JITC Supplement. Ora ...

TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on various solid cancers Data from the first-in-human Phase 1 dose escalation trial demonstrate initial anti-tumor activity and a manageable tolerability profile for TCER® IMA401 monotherapy; patient population includes 35 heavily pre-treated patients across 16 different solid tumor types; dose escalation is ongoing ...

Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine® IMA203 targeting PRAME, will be presented at the 21st International Congress of the Society for Melanoma Research. Oral presentation Date / Time: October 11, 2024 / 8:00 – 8: ...